GlycoMark (1,5-AG) Longevity-Medicine Target Ranges

GlycoMark is the brand name for a blood test that measures serum 1,5-anhydroglucitol (1,5-AG), a dietary sugar alcohol. It is a laboratory assay, not a drug, and it was cleared by the FDA through the 510(k) pathway as an aid to monitoring glycemic control in people with diabetes. It is not itself a diagnostic test for diabetes and it is not FDA-labeled for use in people without diabetes.

Serum 1,5-AG falls when blood glucose repeatedly exceeds roughly 160 to 180 mg/dL, because glucose competes with 1,5-AG for reabsorption in the kidney tubule and both are lost in urine together. That mechanism is well established. What is not established is whether pushing 1,5-AG above the standard diabetic reference range, into the "14 mcg/mL or higher" zone that some longevity-medicine clinics promote as a target for non-diabetic adults, changes cardiovascular or mortality outcomes. That target is a practice pattern built on plausible mechanism and some observational associations, not a guideline-endorsed or FDA-recognized threshold, and this review could not verify the specific effect sizes commonly cited for it. Readers should treat the 14+ mcg/mL figure as a reasonable optimization goal under clinical judgment, not as a validated outcome-linked target.

What GlycoMark measures and why it behaves differently from HbA1c

1,5-Anhydroglucitol is a polyol that comes mostly from the diet and is normally reabsorbed almost completely by the kidney. Glucose and 1,5-AG are reabsorbed through overlapping tubular pathways. When blood glucose rises above roughly 160 to 180 mg/dL, the amount of filtered glucose overwhelms that shared reabsorption capacity, glucose spills into urine, and 1,5-AG is dragged out with it. Because the body's total 1,5-AG pool is small, a single high-glucose meal can measurably deplete it within a day or two. Restoring the pool takes one to two weeks of sustained control below that threshold. This mechanism is well described in the diabetes literature and is the basis for the assay's FDA clearance as a short-window glycemic monitoring aid.

That kinetic profile is what separates GlycoMark from other glycemic markers:

• HbA1c reflects average glucose over roughly the prior three months and does not distinguish a stable moderate average from a pattern of sharp spikes and normal troughs.
• Fructosamine reflects roughly two to three weeks and is less specific to spikes above a threshold; it tracks average glycation of serum proteins generally.
• 1,5-AG is comparatively specific to excursions above the renal threshold and has the shortest recovery window of the three, which is why it is sometimes described as a serum surrogate for continuous glucose monitor (CGM) "time above range."

A person can have a normal HbA1c while having a low 1,5-AG, which happens when frequent postprandial spikes are averaged out by otherwise normal fasting and overnight glucose. This discordance pattern is the main reason clinicians order GlycoMark at all.

Standard reference range versus the longevity-medicine target

The manufacturer's reference range for GlycoMark was built to detect glycemic patterns consistent with diabetes, using cutoffs validated against diagnosed diabetic populations. It answers the question "is this consistent with diabetes-range hyperglycemia," not "is this an optimal level for a healthy adult."

Longevity-medicine practices generally use a higher, unofficial target, most often described as 14 mcg/mL or above, with some clinics aiming higher still. The reasoning is mechanistic and partly observational: cohort studies in adults without diagnosed diabetes have reported that lower 1,5-AG values are associated with a higher burden of cardiovascular risk markers and, in some analyses, higher rates of cardiovascular events, even after adjusting for HbA1c. This review cannot verify the specific hazard ratios, percentages, or cohort sizes that are often quoted alongside these claims, and readers evaluating a specific number should ask their source to point to the underlying published study rather than accept the number on its face. The directionally consistent finding across observational work is that lower 1,5-AG tracks with more cardiovascular risk markers in some study populations; the practice of treating 14 mcg/mL as a target to optimize toward is an extrapolation from that association, not a tested intervention target.

What is established, what is plausible, and what is not established

Established: the mechanism connecting 1,5-AG to recent glucose excursions above the renal threshold; the assay's FDA clearance as an adjunct glycemic monitoring tool in people with diabetes; its shorter recovery window compared with HbA1c and fructosamine; false lowering from renal impairment and from alpha-glucosidase inhibitors (acarbose, miglitol); a distinct lowering effect from SGLT2 inhibitors through a different mechanism (lowering the renal glucose threshold itself).

Plausible but unproven: that raising 1,5-AG through diet, exercise, or medication in a non-diabetic adult who does not otherwise need glucose-lowering therapy reduces long-term cardiovascular or mortality risk. The biological rationale (glucose spikes promote oxidative stress and endothelial dysfunction) is reasonable and supported by mechanistic and short-term physiological studies, but a trial that raises 1,5-AG in non-diabetic adults and follows hard outcomes was not identified for this review.

Not established: any specific numeric target (14 mcg/mL, 19 mcg/mL, or otherwise) as a validated threshold tied to a measured reduction in disease risk in non-diabetic adults. These numbers circulate in longevity-medicine practice but should be presented to patients as clinical judgment, not as a guideline recommendation.

Who this test is likely to help

GlycoMark adds the most information in a few specific situations:

• Normal HbA1c and fasting glucose, but a clinical suspicion of postprandial spikes (family history, prior gestational diabetes, obesity, PCOS, or unexplained fatigue after meals).
• A patient already using a CGM who wants a lab-based cross-check or who cannot access ongoing CGM.
• Someone making an active dietary or medication change who wants feedback faster than the 90 days HbA1c requires.

It adds little for someone with an already-diagnosed diabetes management plan built around CGM data and HbA1c, since those tools already capture the postprandial pattern GlycoMark is inferring indirectly.

Conditions and medications that distort the result

A few factors need to be ruled out before a low GlycoMark is interpreted as evidence of poor glucose control:

• Reduced kidney function. Significant renal impairment reduces tubular handling of both glucose and 1,5-AG and can produce a falsely low result independent of actual glycemic control. Renal function should be checked before relying on an unexpectedly low value.
• Acarbose or miglitol. These alpha-glucosidase inhibitors reduce intestinal absorption of dietary 1,5-AG itself, lowering serum levels without reflecting worse glucose control.
• SGLT2 inhibitors. These drugs work by lowering the kidney's glucose reabsorption threshold, which increases glucosuria at lower blood glucose levels. Because 1,5-AG loss is tied to the same threshold, SGLT2 inhibitor use can lower 1,5-AG even while overall glycemic control is improving. This is a mechanism artifact, not evidence of worse control, and it means GlycoMark is not a reliable monitoring tool for patients on this drug class.
• Pregnancy, severe caloric restriction, and significant liver disease may also shift baseline values; these are less well characterized and warrant clinical judgment rather than a fixed correction factor.

Diet, activity, and medication effects on the result

Reducing the frequency and height of glucose excursions above roughly 180 mg/dL is what raises 1,5-AG over time. Approaches with a reasonable evidence base for reducing postprandial glucose excursions generally include:

• Eating carbohydrate later in a meal rather than first (sometimes called meal sequencing or food order), which has been studied in small trials for its effect on postprandial glucose and insulin.
• Short walks after meals, which several trials and reviews associate with modest reductions in post-meal glucose excursions compared with remaining seated.
• Resistance training, which increases non-insulin-mediated glucose uptake by skeletal muscle for a period after exercise.
• GLP-1 receptor agonists (semaglutide, tirzepatide) and other agents that blunt postprandial glucose through delayed gastric emptying and glucagon suppression, when prescribed for an approved indication such as type 2 diabetes or, in some formulations, obesity. Using these agents specifically to raise a GlycoMark value in a person without an approved indication would be an off-label decision and should be discussed explicitly with a prescriber, including the medication's own risks and monitoring requirements.

Specific percentage reductions in postprandial glucose that are sometimes quoted for these interventions could not be verified against a primary source for this review and are omitted rather than repeated as precise figures. A clinician recommending a specific intervention should be able to point to the trial behind any specific number.

What to expect on retesting

Because the marker's biology involves depletion and slow repletion of a body pool, most clinicians expect a rise in 1,5-AG to lag behind a successful glucose-control intervention by roughly one to two weeks, with continued stabilization over the following weeks. Retesting sooner than about two weeks after a change is unlikely to be informative. If 1,5-AG does not rise despite reported adherence to a glucose-lowering intervention, reasonable next steps include checking for hidden carbohydrate sources, reviewing current medications for acarbose, miglitol, or an SGLT2 inhibitor, and checking kidney function before assuming the intervention failed.

GlycoMark is not a diagnostic test on its own. An unexpectedly low or high value should be interpreted alongside fasting glucose, HbA1c, and clinical context, and a new finding suggestive of undiagnosed diabetes (very low 1,5-AG with symptoms such as unexplained weight loss, excessive thirst, or frequent urination) warrants prompt evaluation by a clinician rather than working the result up through longevity-panel logic alone.

Decision framework: what a GlycoMark result should and should not change

Where this fits with other metabolic markers

GlycoMark is most informative paired with HbA1c and fasting glucose, and, when available, a short period of CGM data. A discordant pattern (normal HbA1c, low GlycoMark) points toward postprandial spikes being masked by an otherwise normal average, which is worth investigating with either a CGM trial or a repeat GlycoMark after a defined dietary change. It is one input among several in a metabolic panel and should not be the sole basis for starting a new medication or making a diagnosis.

When to seek clinical evaluation rather than self-manage a result

An unexpectedly low GlycoMark accompanied by symptoms such as unexplained weight loss, excessive thirst, frequent urination, or blurred vision warrants prompt evaluation for undiagnosed diabetes rather than a longevity-panel workup. A result that is discordant with other labs (for example, very low GlycoMark with normal fasting glucose and HbA1c and no known confounders) is a reasonable trigger for a conversation with a clinician about further testing, including a short CGM trial, rather than a reason to start a supplement or medication on one's own.

References

• U.S. Food and Drug Administration, 510(k) Premarket Notification Database (search for the GlycoMark assay to confirm current clearance status and intended use): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
• American Diabetes Association, Standards of Care in Diabetes (annual, current-year supplement in Diabetes Care) for the current guideline position on postprandial glucose monitoring: https://diabetesjournals.org/care/issue/47/Supplement_1

Certain study references, numerical findings, and guideline quotations from previous versions of this Glycomark article could not be confirmed in original sources during editing and have been either removed or converted to unattributed summaries awaiting clinical team verification. Before publication, any specific quantitative statements added back to this article must be validated directly against their original sources.